Skip to main content

Table 1 Baseline and clinical characteristics of patients with CRSwNP in the modelling group

From: Risk factors associated with comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: a cross-sectional study

Parameter

Whole group (n = 150)

CRSwNP with asthma (n = 80)

CRSwNP without asthma (n = 70)

P value

Female, n (%)

55 (36.7)

39 (48.8)

16 (22.9)

0.001*

Age, years

48.0 (38.0, 56.0)

48.0 (35.3, 55.0)

48.5 (41.0, 59.0)

0.239

BMI, kg/m2

24.2 (22.2, 27.1)

23.5 (21.6, 26.2)

25.2 (23.1, 27.7)

0.019*

Overweight (BMI = 25 ~ 29.9 kg/m2), n (%)

49 (32.7%)

21(26.3)

28 (40.0)

0.073

Obesity (BMI ≥ 30 kg/m2), n (%)

14 (9.3%)

7(8.8%)

7 (10%)

0.793

Smokers, n (%)

44 (29.3)

21 (26.3)

23 (32.9)

0.375

Pack-years smoked

15.0 (9.4, 30.0)

10.0 (7.5, 25.0)

20.0 (10.0, 40.0)

0.110

NSAIDs hypersensitivity, n (%)

19 (12.7)

17 (21.3)

2 (2.9)

0.001*

History of allergic rhinitis, n (%)

44 (29.3)

31 (38.8)

13 (18.6)

0.007*

History of urticaria, n (%)

34 (22.7)

23 (28.7)

11 (15.7)

0.057

History of eczema, n (%)

6 (4.0)

4 (5.0)

2 (2.9)

0.802

Nasal obstruction duration, years

4.0 (1.0, 10.0)

4.0 (2.0, 8.0)

3.0 (1.0, 10.0)

0.549

Blood eosinophil percentage, %

5.0 (3.1, 7.7)

6.1 (4.1, 9.2)

4.5 (2.0, 6.2)

0.001*

Blood eosinophil count, × 109/L

0.3 (0.2, 0.5)

0.4 (0.3, 0.6)

0.3 (0.1, 0.4)

 < 0.001*

Positive eosinophil of nasal secretion, n (%)

47 (31.3)

31 (38.8)

16 (22.9)

0.036*

Serum T-IgE, kU/L

103.5 (38.8, 244.0)

140.0 (73.0, 310.8)

54.2 (30.3, 131.0)

 < 0.001*

Atopy, n (%)

58 (38.7)

33 (41.3)

25 (35.7)

0.487

Dust mite sensitivity, n (%)

43 (28.7)

27 (33.8)

16 (22.9)

0.141

Pollen sensitivity, n (%)

16 (10.7)

7 (8.8)

9 (12.9)

0.416

Animal sensitivity, n (%)

5 (3.3)

4 (5.0)

1 (1.4)

0.447

Cockroach sensitivity, n (%)

8 (5.3)

3 (3.8)

5 (7.1)

0.577

Mold sensitivity, n (%)

3 (2.0)

3 (3.8)

0 (0.0)

0.293

Food sensitivity, n (%)

21 (14.0)

11 (13.8)

10 (14.3)

0.925

FeNO, ppb

27.0 (16.0, 48.0)

35.0 (21.5, 56.8)

20.5 (13.0, 29.0)

 < 0.001*

  1. Data are presented as No. (%) for qualitative variables, as median (25th, 75th percentiles) for abnormal distribution quantitative parameters
  2. CRSwNP Chronic rhinosinusitis with nasal polyps; BMI Body mass index; NSAIDs Non-steroidal anti-inflammatory drugs; T-IgE Total Immunoglobulin E; FeNO Fractional exhaled nitric oxide; ppb Parts per billion
  3. * Statistical significance between CRSwNP with asthma and CRSwNP without asthma